CLINICAL TRIAL SUMMARY

MDACC Study No:2007-0144 (clinicaltrials.gov NCT No: NCT00654732)
Title:A RANDOMIZED PHASE II STUDY OF RITUXIMAB WITH ABVD VERSUS STANDARD ABVD FOR PATIENTS WITH ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA WITH POOR RISK FEATURES (IPS SCORE > 2)
Principal Investigator:Michelle A. Fanale
Treatment Agent:Adriamycin; Bleomycin; Dacarbazine; Rituximab; Vincristine
Study Status:Closed
Study Description:The goal of this clinical research study is to compare the effectiveness of
receiving Adriamycin (doxorubicin hydrochloride), bleomycin, vinblastine, and
dacarbazine (ABVD) therapy alone to receiving ABVD with rituximab.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:Adriamycin
Bleomycin
Dacarbazine
Rituximab
Vincristine
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:Genentech
Return Visit:Every 2 weeks for chemotherapy for 6 months. After treatment ends, patients
will return for follow-up every 3 months for 1st year, every 4 months for 2nd
year, every 6 months for Years 3-5, and annually thereafter.
Home Care:N/A


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michelle A. Fanale
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults